Advisory Board
Jonathan M. Schapiro
|
Jonathan M. Schapiro, MD
jms@stanford.edu
Director, AIDS Service
National Hemophilia Center
Tel Hashomer, Israel
Clinical Assistant Professor
Stanford University School of Medicine
Stanford, California
Date of Birth
July 9, 1960
Education
Ben Gurion University of the Negev, Be'er Sheva, Israel (BMS, 1984)
Ben Gurion University of the Negev, Be'er Sheva, Israel (MD, 1987)
Rabin Medical Center, Petah Tikva, Isreal (Internal Medicine, 1993)
Stanford University School of Medicine (Infectious Diseases and Geographic Medicine, 1996)
Areas of Specialty
Antiretroviral drug resistance, HIV resistance assays, HIV clinical care
Recent Publications
Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.
Durant J, Clevenbergh P, Halfon P, Delgiudice P, porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P. Lancet. 1999 Jun 26;353(9171):2195-9.
Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM, Winters MA, Lawrence J, Merigan TC. AIDS. 1999 Feb 25;13(3):359-65.
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.
Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM, Dellamonica P. AIDS. 2000 Jul 7;14(10):1333-9.
Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons.
Lawrence J, Schapiro J, Winters M, Montoya J, Zolopa A, Pesano R, Efron B, Winslow D, Merigan TC. J Infect Dis. 1999 Jun;179(6):1356-64.
Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333.
Sevin AD, DeGruttola V, Nijhuis M, Schapiro JM, Foulkes AS, Para MF, Boucher CA. J Infect Dis. 2000 Jul;182(1):59-67.
|
